A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

Also called NCT06235086

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 632 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06235086
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06235086. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2026-02-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TG103
Intervention (Drug)
Dulaglutide
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06235086
Content hash
0b2dda8e9e93350e49fb44343592ff84b169f570a19dcfeb5480b47b24bbe874